Floatz logo

Medroxyprogesterone acetate

Pediatric SLE

National Institute of Allergy and Infectious Diseases (NIAID)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Pediatric SLE cohort.

Asset / SponsorPhaseRating
METHOTREXATE
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
Monovalent [B.1.351] Cov2 Pres Dtm-As03
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
JNJ-78436735
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
Monomethyl Fumarate
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
MODERNA COVID-19 VACCINE RNA
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
Tozinameran
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
bnt162b2
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CC

Same molecule, other indications

Medroxyprogesterone acetate is also rated in:

osteoporosisDormant
BBB
Indicative ·
72 / 100
View asset →
cardiovascular disorderDormant
BB
Indicative ·
65 / 100
View asset →
sickle cell diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →